Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Renal Cell 5Prostatic Neoplasms 1Head and Neck Neoplasms 1Clear-cell metastatic renal cell carcinoma 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Nivolumab 14Ipilimumab 11Specimen Handling 10CTLA-4 Antigen 7pembrolizumab 6cabozantinib 6Sunitinib 6Magnetic Resonance Spectroscopy 6Axitinib 5pazopanib 4Biopsy 4Radiosurgery 3lenvatinib 2fludarabine 2Everolimus 2Blood Specimen Collection 2tivozanib 1sodium-iodide symporter 1sitravatinib 1belzutifan 1atezolizumab 1aldesleukin 1Zoledronic Acid 1Tissue Banks 1Selenomethionine 1Radiotherapy 1Radiopharmaceuticals 1Pluvicto 1Nephrectomy 1Molecular Imaging 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Clear-cell metastatic renal cell carcinoma × sitravatinib × Genitourinary × Clear all
NCT04904302 2026-03-20

Sitravatinib and Nivolumab for the Treatment of Metastatic or Advanced Clear Cell Renal Cell Cancer

M.D. Anderson Cancer Center

Phase 2 Terminated
15 enrolled
Genitourinary

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡